Compass Therapeutics Stock Rises 7.4% on Positive News

The biotech company's shares jump after strong analyst ratings and institutional investor activity.

Apr. 16, 2026 at 5:07pm

Got story updates? Submit your updates here. ›

An extreme close-up photograph of the intricate mechanical components and machinery found in a biotech laboratory, representing the technical complexity of Compass Therapeutics' drug development process.The complex machinery behind Compass Therapeutics' innovative cancer therapies drives investor optimism.Cambridge Today

Shares of Compass Therapeutics (NASDAQ:CMPX) rose 7.4% on Thursday, trading as high as $6.18 per share. The jump came on the back of positive analyst ratings, with several firms maintaining 'buy' recommendations and price targets as high as $30 for the clinical-stage biotech company.

Why it matters

Compass Therapeutics is developing novel immuno-oncology therapies, an area of high interest and growth potential in the pharmaceutical industry. The stock's performance and analyst sentiment reflect investor optimism around the company's pipeline and future prospects.

The details

Compass Therapeutics saw trading volume decline 83% from its average daily levels, with around 383,529 shares changing hands. The stock closed at $6.28, up from the previous close of $5.85. Analysts have cited the company's lead programs, including the bispecific antibody CTX-471 and the CD47-SIRPα pathway modulator DSP107, as drivers of their positive outlook.

  • Compass Therapeutics stock rose 7.4% during trading on Thursday, April 16, 2026.

The players

Compass Therapeutics, Inc.

A clinical-stage biotechnology company dedicated to developing novel immuno-oncology therapies, headquartered in Cambridge, Massachusetts.

Weiss Ratings

A research firm that has rated Compass Therapeutics stock as a 'sell (d-)'.

Cantor Fitzgerald

An investment bank that has maintained an 'overweight' rating on Compass Therapeutics shares.

D. Boral Capital

An investment firm that has reaffirmed a 'buy' rating and $30 price target on Compass Therapeutics stock.

Guggenheim

A financial services firm that has reaffirmed a 'buy' rating and $12 price target on Compass Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“Compass Therapeutics has a promising pipeline of immuno-oncology therapies that could drive significant value for shareholders.”

— D. Boral, Analyst

“We remain confident in Compass Therapeutics' ability to advance its lead programs and deliver positive results for patients.”

— Guggenheim Analyst

What’s next

Compass Therapeutics is expected to provide updates on the progress of its clinical trials in the coming months, which could further impact the stock price.

The takeaway

Compass Therapeutics' strong stock performance and positive analyst sentiment underscore the growing investor interest in the company's innovative approach to immuno-oncology treatments, which could lead to significant advancements in cancer care.